Physician profile
Jose E Mendez
NPI 1033101175
$1,277.76
in general payments reported to CMS, 2019-2025
20 companies · $59.20 in 2025
The $59.20 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $12.84 · 2021: $46.73 · 2022: $191 · 2023: $111 · 2024: $672 · 2025: $59.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.21 |
| Education | $224.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $368.38 | 2021-2025 | Tremfya |
| Abbvie INC. | $194.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.98 | 2024 | Sotyktu |
| Amgen INC. | $84.34 | 2019-2024 | Otezla |
| Strata Skin Sciences, INC. | $66.09 | 2019-2023 | Xtrac |
| Incyte Corporation | $64.58 | 2024 | Opzelura |
| Kerecis Limited | $62.19 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pfizer INC. | $51.67 | 2019-2022 | |
| Lilly USA, LLC | $46.25 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $42.19 | 2024 | |
| Organogenesis INC. | $39.09 | 2023 | Puraply |
| Regeneron Healthcare Solutions, INC. | $30.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.73 | 2023 | Spevigo |
| Genzyme Corporation | $20.44 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $18.78 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.67 | 2022 | |
| Galderma Laboratories, L.P. | $13.47 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.